Heart Attack
Research from University of Texas has provided new information about heart attack
Published in Drug Week, June 13th, 2008
According to a study from the United States, "To evaluate the cost-effectiveness of first-line treatments for hypertension. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) found that first-line treatment with lisinopril or amlodipine was not significantly superior to chlorthalidone in terms of the primary endpoint, so differences in costs may be critical for optimizing decision-making."
"Cost-effectiveness analysis was performed using bootstrap resampling to evaluate uncertainty. Over a patient's lifetime, chlorthalidone was always least expensive (mean $4,802 less than amlodipine, $3,700 less than lisinopril). Amlodipine...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
Source: Drug Week (2008-06-13)
More Articles from Drug Week
- American Academy of Neurology
Guideline: Vertigo can be treated easily and quickly - American Academy of Neurology
Ibuprofen, aspirin, naproxen may be equally effective at reducing risk of Alzheimer's disease - Beth Israel Deaconess Medical Center
New method effective in detecting dangerous coronary plaque - Children's Hospital of Pittsburgh
Pittsburgh scientists find protein may be key to new therapies for elevated triglycerides - JAMA and Archives Journals
Prevalence of obesity among US children and teens does not increase - JAMA and Archives Journals
Therapies appear helpful in reducing risk of depression following stroke - More from this issue of Drug Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
